News
Interview with Richard Yu, PhD Co-Founder & CEO, Abalone Bio
Download full version here
Abalone Bio is a preclinical stage drug discovery company that creates antibodies that go beyond the existing capabilities of antibody drugs to activate challenging drug targets to access promising disease-treating biology. Antibodies are molecules originally used by our immune system to shut stuff down- kill invading bacteria and viruses- but what we want to do is fulfill the full drug-like potential of these wonderful molecules. Many targets that need to be activated to treat diseases haven’t been addressable by other drug types, and we can create antibodies to twiddle those receptor “control knobs” on the surfaces of our cells, like G-protein coupled receptors, to access therapeutic biological activities. We’re developing one anti-inflammatory drug for neuropathic pain, and we also have a discovery stage pipeline focusing primarily on metabolic disorders but also on cancer and inflammation. What they share is a focus on targets that we believe are best- or perhaps only- activated by an antibody drug.
Read more downloading our interview!